Nasal spray formulations of BPC-157 and TB-500 represent a specialized area of peptide formulation science. This page provides an educational overview of the composition, stability considerations, and laboratory standards involved in preparing and characterizing peptide nasal spray formulations for research purposes.
1.BPC-157 And TB-500 Nasal Delivery Formulation Overview
A nasal spray formulation is a liquid preparation designed for administration to the nasal mucosa. In the context of peptide research, nasal spray formulations contain dissolved peptide(s) in an aqueous vehicle with various excipients. The formulation must achieve specific physical properties—including appropriate viscosity, pH, and droplet size—to be suitable for nasal delivery research.
For BPC-157 and TB-500 nasal spray formulations, the peptide is dissolved in a buffered aqueous solution rather than presented as a lyophilized powder. This liquid state introduces different stability and handling considerations compared to the dry form. See our dosage forms page for comparison with other presentation forms.
2.BPC-157 And TB-500 Excipient Composition
A peptide nasal spray formulation typically contains several categories of excipients, each serving a specific function:
- Buffer system – Phosphate or citrate buffers to maintain pH in the 5.0-6.5 range, which is generally tolerated by nasal mucosa in research models
- Tonicity agent – Sodium chloride or mannitol to achieve isotonicity (~290 mOsm/kg), matching physiological conditions
- Preservative – Benzyl alcohol (0.5-1.0%) or other antimicrobial agents to prevent microbial contamination in multi-dose containers
- Viscosity modifier – Hydroxypropyl methylcellulose (HPMC) or similar polymers to adjust spray characteristics
- Solubilizer – If needed, to maintain peptide solubility at the target concentration
The specific excipient selection depends on the peptide's physicochemical properties. BPC-157, being a smaller peptide (15 amino acids, ~1,419.55 g/mol), typically demonstrates good aqueous solubility. TB-500, at 43 amino acids (~4,963.55 g/mol), may require additional formulation strategies to maintain solubility at higher concentrations.
3.BPC-157 And TB-500 Stability Considerations
Nasal spray formulations present unique stability challenges compared to lyophilized forms. In aqueous solution, peptides are more susceptible to:
- Hydrolysis – Breakdown of peptide bonds in aqueous media, accelerated at extreme pH values
- Aggregation – Formation of peptide aggregates, particularly at higher concentrations
- Deamidation – Conversion of asparagine or glutamine residues to aspartic or glutamic acid
- Oxidation – Particularly relevant for TB-500, which contains a methionine residue susceptible to oxidation
To mitigate these stability concerns, nasal spray formulations are typically stored at 2-8°C and protected from light. Antioxidants such as methionine (as a sacrificial oxidant) may be included in TB-500 formulations. The recommended shelf life for peptide nasal spray formulations is generally shorter than for lyophilized products.
4.BPC-157 And TB-500 Concentration and Dosing Volume
Nasal spray formulations are typically prepared at lower peptide concentrations compared to injectable forms. Common research concentrations range from 0.5 mg/mL to 5 mg/mL. The delivery volume per actuation (spray) is typically 50-100 microliters (µL), meaning each spray delivers a small amount of peptide.
| Formulation | Concentration | Volume per Spray | Peptide per Spray |
|---|---|---|---|
| BPC-157 Low | 1 mg/mL | 100 µL | 0.1 mg |
| BPC-157 Standard | 5 mg/mL | 100 µL | 0.5 mg |
| TB-500 Low | 0.5 mg/mL | 100 µL | 0.05 mg |
| TB-500 Standard | 2 mg/mL | 100 µL | 0.2 mg |
5.BPC-157 And TB-500 Container and Delivery Device
Nasal spray formulations are housed in metered-dose spray containers. These devices consist of a bottle, a pump mechanism, and a nozzle. The pump is calibrated to deliver a consistent volume per actuation. For research purposes, the consistency of dosing volume is a critical parameter that must be validated during formulation development.
Materials compatibility is also important—the formulation must not interact with the container materials. Amber glass bottles are commonly used to protect the peptide from light exposure. For more information about other delivery device types, see our pen delivery system page and injection preparation page.
6.BPC-157 And TB-500 Quality Control Parameters
Quality control for peptide nasal spray formulations includes testing for peptide content (by UV spectrophotometry or HPLC), pH, osmolality, microbial limits, and spray pattern uniformity. Each batch should be accompanied by a Certificate of Analysis documenting these parameters. For information about research quality standards, see our research protocol page.